Business Updates:
• Revenue drop YoY, however volumes is same.
• Autonomous driving trend is long term trend which requires software for multiple use.
• Shared Mobility is also showing good trend. For this vehicle replacement with software inbuilt can be seen.
• Company has made strategies to intake efficient employees
• Company focus is to attract few clients but to have very long term plan with those customers.
Deals and Pipelines:
• Pipeline has been increased at highest in the last quarter, which is across the region and verticals.
• Electric Power train has grown marginally, but company expect much of the growth to be coming from Electric Power train.
• Got few deals in OEM
Revenue Share and Margin:
• Revenue Share of quarter in image
• Offshoring is expected to be increasing and company is looking for margins improvement.
• Fixed PRice engagement have gone up for productivity side, and company is expected to see growth productivity as well.
Competitive Landscape:
• There are companies are like Luxoft in Software and technology, and there are certain OEM who wants to own the software.
• Company is working in Tier 1, with their own software.
• Current Run rate is 12%.
Focus:
• Company is engage with semiconductor companies for software past (some software called middle ware).
• Semi Conductor will not be the direct customer but this can be helpful for indirectly connecting with OEM
Commercial Vehicle (CV):
• Growth in electrification in CV and the area of focus remains the same as other vehicle.
• On Autonomous vehicle company has strong focus, as area of scope is wide.
• Company don't see any softness in the autonomous side. Both domestic and export.
T25 Clients:
• These are designated client where company investment over more on the long term contracts with customer. Company is do seeing adding and improving these client list as well.
Risk on Software:
• It is similar to that of software development.
• Main focus remains on quality of product.
• Company has focus of defect free delivery.
Business Updates:
• Oncology business is expected to grow well.
• CRM manufacturing of API and ARV and Non ARV segment is seen good growth.
• Adding manufacturing facility for ARV and Non ARV.
• Revenue share mentioned in image.
• Acquire land at Vizag at existing facility for increasing capacity.
• Planning to buy land for Laurus Bio.
• Planning for separate Synthesis company as company is planning to expand well in these segment.
• Most of US sales is contract manufacturing
"Big Pond (Industry Scope) with few Big Fishes (less players) seems good. But Uncertainty and Fear of Competitor can also tamper down the growing size of Fish (stable growth)"
Here are the key insights 😀
Business Updates:
• Total Traffic grew by 44%.
• 80 Millions every month which was 52 Million last year same month.
• For beginning of this quarter company came to pre covid level and in quarter end there is 4000 net addition and supplier base of 1,52,000.
• Company is continue focusing on acquisition as well.
• 1070 crores QIP was successful in Q4 which will be utilized for expansion.